Altimmune (ALT) Depreciation & Amortization (CF) (2010 - 2026)
Altimmune (ALT) reported Depreciation & Amortization (CF) of $23000.0 for Q1 2026, down 20.69% year-over-year from $29000.0 in Q1 2025, and up 64.29% quarter-over-quarter from $14000.0 in Q4 2025.
Altimmune (ALT) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $23000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $23000.0, down 20.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $94000.0 (down 22.95% YoY), and the FY2025 annual result was $100000.0, down 50.0% from the prior year.
- Depreciation & Amortization (CF) climbed to $23000.0 in Q1 2026 per ALT's latest filing, from $14000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $137000.0 in Q4 2023 and troughed at -$552000.0 in Q3 2023.
- A 5-year average of -$68117.6 and a median of $27000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) sank 1052.83% in 2023, then surged 380.0% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at -$236000.0 in 2022, then surged by 158.05% to $137000.0 in 2023, then plunged by 103.65% to -$5000.0 in 2024, then surged by 380.0% to $14000.0 in 2025, then surged by 64.29% to $23000.0 in 2026.
- Business Quant data shows ALT's Depreciation & Amortization (CF) at $23000.0 in Q1 2026, $14000.0 in Q4 2025, and $27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Dec 31, 2023 | 137,000.00 |
| Dec 31, 2023 | 137,000.00 |